| Year |
Citation |
Score |
| 2023 |
Pierce KK, Durbin AP, Walsh MC, Carmolli M, Sabundayo BP, Dickson DM, Diehl SA, Whitehead SS, Kirkpatrick BD. TV005 dengue vaccine protects against dengue serotype 2 and 3 controlled human infection. The Journal of Clinical Investigation. PMID 37971871 DOI: 10.1172/JCI173328 |
0.412 |
|
| 2023 |
Walsh MR, Alam MS, Pierce KK, Carmolli M, Alam M, Dickson DM, Bak DM, Afreen S, Nazib F, Golam K, Qadri F, Diehl SA, Durbin AP, Whitehead SS, Haque R, et al. Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial. The Lancet. Infectious Diseases. PMID 37776876 DOI: 10.1016/S1473-3099(23)00520-0 |
0.37 |
|
| 2023 |
Odio CD, Lowman KE, Law M, Aogo RA, Hunsberger S, Wood BJ, Kassin M, Levy E, Callier V, Firdous S, Hasund CM, Voirin C, Kattappuram R, Yek C, Manning J, ... Durbin A, et al. Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine. Bmc Infectious Diseases. 23: 345. PMID 37221466 DOI: 10.1186/s12879-023-08299-5 |
0.397 |
|
| 2023 |
Pintado Silva J, Fenutria R, Bernal-Rubio D, Sanchez-Martin I, Hunziker A, Chebishev E, Veloz J, Kelly G, Kim-Schulze S, Whitehead S, Durbin A, Ramos I, Fernandez-Sesma A. The dengue virus 4 component of NIAID's tetravalent TV003 vaccine drives its innate immune signature. Experimental Biology and Medicine (Maywood, N.J.). 247: 2201-2212. PMID 36734144 DOI: 10.1177/15353702231151241 |
0.393 |
|
| 2023 |
Wilder-Smith A, Durbin A. Promising efforts to develop an mRNA vaccine against Zika. The Lancet. Infectious Diseases. PMID 36682366 DOI: 10.1016/S1473-3099(22)00827-1 |
0.305 |
|
| 2022 |
Wong JM, Adams LE, Durbin AP, Muñoz-Jordán JL, Poehling KA, Sánchez-González LM, Volkman HR, Paz-Bailey G. Dengue: A Growing Problem With New Interventions. Pediatrics. PMID 35543085 DOI: 10.1542/peds.2021-055522 |
0.322 |
|
| 2022 |
Hou R, Tomalin LE, Silva JP, Kim-Schulze S, Whitehead SS, Fernandez-Sesma A, Durbin AP, Suárez-Fariñas M. The innate immune response following multivalent dengue vaccination and implications for protection against dengue challenge. Jci Insight. PMID 35511431 DOI: 10.1172/jci.insight.157811 |
0.364 |
|
| 2022 |
Santiago HC, Pereira-Neto TA, Gonçalves-Pereira MH, Terzian ACB, Durbin AP. Peculiarities of Zika Immunity and Vaccine Development: Lessons from Dengue and the Contribution from Controlled Human Infection Model. Pathogens (Basel, Switzerland). 11. PMID 35335618 DOI: 10.3390/pathogens11030294 |
0.386 |
|
| 2021 |
Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, McEvoy C, DeJesus E, Hassman M, Little SJ, Pahud BA, ... Durbin A, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. The New England Journal of Medicine. PMID 34587382 DOI: 10.1056/NEJMoa2105290 |
0.317 |
|
| 2021 |
Fongwen N, Delrieu I, Ham LH, Gubler DJ, Durbin A, Ooi EE, Peeling RW, Flasche S, Hartigan-Go K, Clifford S, Martinez CT, de Lamballerie X, Barnighausen T, Wilder-Smith A. Implementation strategies for the first licensed dengue vaccine: A meeting report. Vaccine. PMID 34253416 DOI: 10.1016/j.vaccine.2021.06.083 |
0.34 |
|
| 2021 |
See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, Streiff MB, Rao AK, Wheeler AP, Beavers SF, Durbin AP, Edwards K, Miller E, Harrington TA, Mba-Jonas A, et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. Jama. PMID 33929487 DOI: 10.1001/jama.2021.7517 |
0.33 |
|
| 2021 |
Nivarthi UK, Swanstrom J, Delacruz MJ, Patel B, Durbin AP, Whitehead SS, Kirkpatrick BD, Pierce KK, Diehl SA, Katzelnick L, Baric RS, de Silva AM. A tetravalent live attenuated dengue virus vaccine stimulates balanced immunity to multiple serotypes in humans. Nature Communications. 12: 1102. PMID 33597521 DOI: 10.1038/s41467-021-21384-0 |
0.426 |
|
| 2020 |
Tu HA, Nivarthi UK, Graham NR, Eisenhauer P, Delacruz MJ, Pierce KK, Whitehead SS, Boyson JE, Botten JW, Kirkpatrick BD, Durbin AP, deSilva AM, Diehl SA. Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003. Cell Reports. Medicine. 1: 100155. PMID 33377126 DOI: 10.1016/j.xcrm.2020.100155 |
0.369 |
|
| 2020 |
Durbin AP. Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005. Current Opinion in Virology. 43: 79-87. PMID 33164790 DOI: 10.1016/j.coviro.2020.09.005 |
0.402 |
|
| 2020 |
Martinez DR, Yount B, Nivarthi U, Munt JE, Delacruz MJ, Whitehead SS, Durbin AP, de Silva AM, Baric RS. Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees. Cell Reports. 33: 108226. PMID 33027653 DOI: 10.1016/j.celrep.2020.108226 |
0.363 |
|
| 2020 |
Levine MM, Abdullah S, Arabi YM, Darko DM, Durbin AP, Estrada V, Jamrozik E, Kremsner PG, Lagos R, Pitisuttithum P, Plotkin SA, Sauerwein R, Shi SL, Sommerfelt H, Subbarao K, et al. Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-Monitored Challenge Model of COVID-19 in Healthy Volunteers. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32857836 DOI: 10.1093/cid/ciaa1290 |
0.306 |
|
| 2020 |
Pollard AJ, Sauerwein R, Baay M, Neels P, Balasingam S, Bejon P, Berthels N, Bull S, Catchpole A, Chi PC, Chilengi R, Cox R, Davies H, Durbin A, et al. Third human challenge trial conference, Oxford, United Kingdom, February 6-7, 2020, a meeting report. Biologicals : Journal of the International Association of Biological Standardization. PMID 32505512 DOI: 10.1016/J.Biologicals.2020.04.004 |
0.359 |
|
| 2020 |
Durbin AP, Pierce KK, Kirkpatrick BD, Grier P, Sabundayo BP, He H, Sausser M, Russell AF, Martin J, Hyatt D, Cook M, Sachs JR, Wen-Tseng Lee A, Wang L, Coller BA, et al. Immunogenicity and Safety of a Tetravalent Recombinant Subunit Dengue Vaccine in Adults Previously Vaccinated with a Live Attenuated Tetravalent Dengue Vaccine: Results of a Phase-I Randomized Clinical Trial. The American Journal of Tropical Medicine and Hygiene. PMID 32394880 DOI: 10.4269/ajtmh.20-0042 |
0.395 |
|
| 2020 |
Kallas EG, Precioso AR, Palacios R, Thomé B, Braga PE, Vanni T, Campos LMA, Ferrari L, Mondini G, da Graça Salomão M, da Silva A, Espinola HM, do Prado Santos J, Santos CLS, Timenetsky MDCST, ... ... Durbin AP, et al. Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial. The Lancet. Infectious Diseases. PMID 32220283 DOI: 10.1016/S1473-3099(20)30023-2 |
0.353 |
|
| 2020 |
Durbin AP, Gubler DJ. What is the prospect of a safe and effective dengue vaccine for travellers? Journal of Travel Medicine. 26. PMID 30657935 DOI: 10.1093/jtm/tay153 |
0.354 |
|
| 2019 |
Krubiner CB, Faden RR, Karron RA, Little MO, Lyerly AD, Abramson JS, Beigi RH, Cravioto AR, Durbin AP, Gellin BG, Gupta SB, Kaslow DC, Kochhar S, Luna F, Saenz C, et al. Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response. Vaccine. PMID 31060949 DOI: 10.1016/J.Vaccine.2019.01.011 |
0.316 |
|
| 2019 |
Swanstrom JA, Nivarthi UK, Patel B, Delacruz MJ, Yount B, Widman DG, Durbin AP, Whitehead SS, de Silva AM, Baric RS. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by NIH Monovalent Dengue Virus Vaccines. The Journal of Infectious Diseases. PMID 30895307 DOI: 10.1093/Infdis/Jiz109 |
0.385 |
|
| 2018 |
Gallichotte EN, Baric TJ, Nivarthi U, Delacruz MJ, Graham R, Widman DG, Yount BL, Durbin AP, Whitehead SS, de Silva AM, Baric RS. Genetic Variation between Dengue Virus Type 4 Strains Impacts Human Antibody Binding and Neutralization. Cell Reports. 25: 1214-1224. PMID 30380413 DOI: 10.1016/J.Celrep.2018.10.006 |
0.321 |
|
| 2018 |
Keasey S, Smith J, Fernandez S, Durbin A, Zhao B, Ulrich RG. Impact of dengue virus serotype 2 strain diversity on serological immune responses to dengue. Acs Infectious Diseases. PMID 30347144 DOI: 10.1021/acsinfecdis.8b00185 |
0.328 |
|
| 2018 |
Popper SJ, Strouts FR, Lindow JC, Cheng HK, Montoya M, Balmaseda A, Durbin AP, Whitehead SS, Harris E, Kirkpatrick BD, Relman DA. Early transcriptional responses after dengue vaccination mirror the response to natural infection and predict neutralizing antibody titers. The Journal of Infectious Diseases. PMID 30010906 DOI: 10.1093/Infdis/Jiy434 |
0.372 |
|
| 2018 |
Wilder-Smith A, Vannice K, Durbin A, Hombach J, Thomas SJ, Thevarjan I, Simmons CP. Zika vaccines and therapeutics: landscape analysis and challenges ahead. Bmc Medicine. 16: 84. PMID 29871628 DOI: 10.1186/S12916-018-1067-X |
0.367 |
|
| 2018 |
Vannice KS, Wilder-Smith A, Barrett ADT, Carrijo K, Cavaleri M, de Silva A, Durbin AP, Endy T, Harris E, Innis BL, Katzelnick LC, Smith PG, Sun W, Thomas SJ, Hombach J. Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines. Vaccine. PMID 29525283 DOI: 10.1016/J.Vaccine.2018.02.062 |
0.375 |
|
| 2018 |
Gallichotte EN, Baric TJ, Yount BL, Widman DG, Durbin A, Whitehead S, Baric RS, de Silva AM. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes. Plos Pathogens. 14: e1006934. PMID 29481552 DOI: 10.1371/Journal.Ppat.1006934 |
0.361 |
|
| 2017 |
Durbin AP, Whitehead SS. Zika Vaccines: Role for Controlled Human Infection. The Journal of Infectious Diseases. 216: S971-S975. PMID 29267920 DOI: 10.1093/infdis/jix491 |
0.395 |
|
| 2017 |
Talaat KR, Halsey NA, Cox AB, Coles CL, Durbin AP, Ramakrishnan A, Bream JH. Rapid changes in serum cytokines and chemokines in response to inactivated influenza vaccination. Influenza and Other Respiratory Viruses. PMID 28991404 DOI: 10.1111/irv.12509 |
0.32 |
|
| 2017 |
Robinson ML, Durbin AP. Dengue vaccines: implications for dengue control. Current Opinion in Infectious Diseases. PMID 28719400 DOI: 10.1097/QCO.0000000000000394 |
0.369 |
|
| 2017 |
Durbin A, Wilder-Smith A. An update on Zika vaccine developments. Expert Review of Vaccines. PMID 28633549 DOI: 10.1080/14760584.2017.1345309 |
0.378 |
|
| 2017 |
Whitehead SS, Durbin AP, Pierce KK, Elwood D, McElvany BD, Fraser EA, Carmolli MP, Tibery CM, Hynes NA, Jo M, Lovchik JM, Larsson CJ, Doty EA, Dickson DM, Luke CJ, et al. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. Plos Neglected Tropical Diseases. 11: e0005584. PMID 28481883 DOI: 10.1371/journal.pntd.0005584 |
0.344 |
|
| 2017 |
Pierce KK, Whitehead SS, Kirkpatrick BD, Grier PL, Jarvis A, Kenney H, Carmolli MP, Reynolds C, Tibery CM, Lovchik J, Janiak A, Luke CJ, Durbin AP, Pletnev AG. A Live Attenuated Chimeric West Nile Virus Vaccine, rWN/DEN4Δ30, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers. The Journal of Infectious Diseases. 215: 52-55. PMID 28077583 DOI: 10.1093/infdis/jiw501 |
0.349 |
|
| 2017 |
Durbin AP. A Dengue Vaccine. Cell. 166: 1. PMID 27368091 DOI: 10.1016/j.cell.2016.06.036 |
0.347 |
|
| 2016 |
Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE, de Silva AM. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and Vaccination. Journal of Virology. PMID 28031369 DOI: 10.1128/Jvi.02041-16 |
0.343 |
|
| 2016 |
Angelo MA, Grifoni A, O'Rourke PH, Sidney J, Paul S, Peters B, de Silva AD, Phillips E, Mallal S, Diehl SA, Kirkpatrick BD, Whitehead SS, Durbin AP, Sette A, Weiskopf D. Human CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificity. Journal of Virology. PMID 27974563 DOI: 10.1128/JVI.02147-16 |
0.302 |
|
| 2016 |
Talaat KR, Ellis RD, Hurd J, Hentrich A, Gabriel E, Hynes NA, Rausch KM, Zhu D, Muratova O, Herrera R, Anderson C, Jones D, Aebig J, Brockley S, MacDonald NJ, ... ... Durbin AP, et al. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. Plos One. 11: e0163144. PMID 27749907 DOI: 10.1371/Journal.Pone.0163144 |
0.376 |
|
| 2016 |
Durbin AP. Vaccine Development for Zika Virus-Timelines and Strategies. Seminars in Reproductive Medicine. PMID 27607566 DOI: 10.1055/s-0036-1592070 |
0.378 |
|
| 2016 |
Kirkpatrick BD, Whitehead SS, Pierce KK, Tibery CM, Grier PL, Hynes NA, Larsson CJ, Sabundayo BP, Talaat KR, Janiak A, Carmolli MP, Luke CJ, Diehl SA, Durbin AP. The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model. Science Translational Medicine. 8: 330ra36. PMID 27089205 DOI: 10.1126/scitranslmed.aaf1517 |
0.41 |
|
| 2016 |
Vannice KS, Durbin A, Hombach J. Status of vaccine research and development of vaccines for dengue. Vaccine. PMID 26973072 DOI: 10.1016/j.vaccine.2015.12.073 |
0.347 |
|
| 2015 |
Vannice KS, Keita M, Sow SO, Durbin AP, Omer SB, Moulton LH, Yaméogo TM, Zuber PL, Onwuchekwa U, Sacko M, Diomandé FV, Halsey NA. Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 61: S493-500. PMID 26553680 DOI: 10.1093/Cid/Civ497 |
0.372 |
|
| 2015 |
Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE, de Silva AM, Baric RS. A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is the Target of Durable Type-Specific Neutralizing Antibodies. Mbio. 6. PMID 26463165 DOI: 10.1128/Mbio.01461-15 |
0.409 |
|
| 2015 |
Larsen CP, Whitehead SS, Durbin AP. Dengue human infection models to advance dengue vaccine development. Vaccine. 33: 7075-82. PMID 26424605 DOI: 10.1016/J.Vaccine.2015.09.052 |
0.422 |
|
| 2015 |
Katzelnick LC, Fonville JM, Gromowski GD, Bustos Arriaga J, Green A, James SL, Lau L, Montoya M, Wang C, VanBlargan LA, Russell CA, Thu HM, Pierson TC, Buchy P, Aaskov JG, ... ... Durbin A, et al. Dengue viruses cluster antigenically but not as discrete serotypes. Science (New York, N.Y.). 349: 1338-43. PMID 26383952 DOI: 10.1126/Science.Aac5017 |
0.392 |
|
| 2015 |
Schwartz LM, Halloran ME, Durbin AP, Longini IM. The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine. 33: 3293-3298. PMID 25989449 DOI: 10.1016/J.Vaccine.2015.05.010 |
0.366 |
|
| 2015 |
Tsai WY, Durbin A, Tsai JJ, Hsieh SC, Whitehead S, Wang WK. Complexity of neutralization antibodies against multiple dengue viral serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies. Journal of Virology. PMID 25972550 DOI: 10.1128/Jvi.00273-15 |
0.395 |
|
| 2015 |
Kirkpatrick BD, Durbin AP, Pierce KK, Carmolli MP, Tibery CM, Grier PL, Hynes N, Diehl SA, Elwood D, Jarvis AP, Sabundayo BP, Lyon CE, Larsson CJ, Jo M, Lovchik JM, et al. Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. The Journal of Infectious Diseases. PMID 25801652 DOI: 10.1093/infdis/jiv082 |
0.376 |
|
| 2014 |
Mukherjee S, Dowd KA, Manhart CJ, Ledgerwood JE, Durbin AP, Whitehead SS, Pierson TC. Mechanism and significance of cell type-dependent neutralization of flaviviruses. Journal of Virology. 88: 7210-20. PMID 24741083 DOI: 10.1128/Jvi.03690-13 |
0.345 |
|
| 2014 |
Smolynets O, Pierce K, Greene L, Diehl S, Taatjes D, Durbin A, Whitehead S, Kirkpatrick B. 1478Dermatologic Manifestations in Live Attenuated Dengue Vaccines: A Skin Biopsy Study Open Forum Infectious Diseases. 1. DOI: 10.1093/Ofid/Ofu052.1024 |
0.378 |
|
| 2013 |
VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. Plos Pathogens. 9: e1003761. PMID 24348242 DOI: 10.1371/Journal.Ppat.1003761 |
0.414 |
|
| 2013 |
Durbin AP, Wright PF, Cox A, Kagucia W, Elwood D, Henderson S, Wanionek K, Speicher J, Whitehead SS, Pletnev AG. The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers. Vaccine. 31: 5772-7. PMID 23968769 DOI: 10.1016/j.vaccine.2013.07.064 |
0.393 |
|
| 2013 |
Lindow JC, Durbin AP, Whitehead SS, Pierce KK, Carmolli MP, Kirkpatrick BD. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. Vaccine. 31: 3347-52. PMID 23735680 DOI: 10.1016/j.vaccine.2013.05.075 |
0.305 |
|
| 2013 |
Bentsi-Enchill AD, Schmitz J, Edelman R, Durbin A, Roehrig JT, Smith PG, Hombach J, Farrar J. Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation. Vaccine. 31: 2603-9. PMID 23570986 DOI: 10.1016/J.Vaccine.2013.03.038 |
0.428 |
|
| 2013 |
Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. The Journal of Infectious Diseases. 207: 1898-908. PMID 23526830 DOI: 10.1093/infdis/jit119 |
0.387 |
|
| 2013 |
Durbin AP, Mayer SV, Rossi SL, Amaya-Larios IY, Ramos-Castaneda J, Eong Ooi E, Jane Cardosa M, Munoz-Jordan JL, Tesh RB, Messer WB, Weaver SC, Vasilakis N. Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity. Virology. 439: 34-41. PMID 23485373 DOI: 10.1016/J.Virol.2013.01.018 |
0.373 |
|
| 2013 |
Durbin AP, Kirkpatrick BD, Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. The Journal of Infectious Diseases. 207: 957-65. PMID 23329850 DOI: 10.1093/infdis/jis936 |
0.321 |
|
| 2012 |
Ellis RD, Wu Y, Martin LB, Shaffer D, Miura K, Aebig J, Orcutt A, Rausch K, Zhu D, Mogensen A, Fay MP, Narum DL, Long C, Miller L, Durbin AP. Phase 1 study in malaria naïve adults of BSAM2/Alhydrogel®+CPG 7909, a blood stage vaccine against P. falciparum malaria. Plos One. 7: e46094. PMID 23056238 DOI: 10.1371/journal.pone.0046094 |
0.326 |
|
| 2012 |
Lindow JC, Borochoff-Porte N, Durbin AP, Whitehead SS, Fimlaid KA, Bunn JY, Kirkpatrick BD. Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans. Plos Neglected Tropical Diseases. 6: e1742. PMID 22816004 DOI: 10.1371/journal.pntd.0001742 |
0.31 |
|
| 2011 |
Durbin AP, Whitehead SS. Next-generation dengue vaccines: Novel strategies currently under development Viruses. 3: 1800-1814. PMID 22069516 DOI: 10.3390/v3101800 |
0.391 |
|
| 2011 |
Durbin AP, Whitehead SS, Shaffer D, Elwood D, Wanionek K, Thumar B, Blaney JE, Murphy BR, Schmidt AC. A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. Plos Neglected Tropical Diseases. 5: e1267. PMID 21829748 DOI: 10.1371/journal.pntd.0001267 |
0.393 |
|
| 2011 |
Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS. Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine. 29: 7242-50. PMID 21781997 DOI: 10.1016/j.vaccine.2011.07.023 |
0.388 |
|
| 2011 |
Durbin AP, Schmidt A, Elwood D, Wanionek KA, Lovchik J, Thumar B, Murphy BR, Whitehead SS. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic. The Journal of Infectious Diseases. 203: 327-34. PMID 21208923 DOI: 10.1093/infdis/jiq059 |
0.37 |
|
| 2010 |
Ellis RD, Sagara I, Durbin A, Dicko A, Shaffer D, Miller L, Assadou MH, Kone M, Kamate B, Guindo O, Fay MP, Diallo DA, Doumbo OK, Emanuel EJ, Millum J. Comparing the understanding of subjects receiving a candidate malaria vaccine in the United States and Mali. The American Journal of Tropical Medicine and Hygiene. 83: 868-72. PMID 20889881 DOI: 10.4269/Ajtmh.2010.10-0062 |
0.343 |
|
| 2010 |
Cassetti MC, Durbin A, Harris E, Rico-Hesse R, Roehrig J, Rothman A, Whitehead S, Natarajan R, Laughlin C. Report of an NIAID workshop on dengue animal models. Vaccine. 28: 4229-34. PMID 20434551 DOI: 10.1016/J.Vaccine.2010.04.045 |
0.377 |
|
| 2009 |
Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, Schmidt AC. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers. The American Journal of Tropical Medicine and Hygiene. 81: 834-41. PMID 19861619 DOI: 10.4269/Ajtmh.2009.09-0131 |
0.397 |
|
| 2009 |
Durbin AP, Whitehead SS. Dengue vaccine candidates in development Current Topics in Microbiology and Immunology. 338: 129-143. PMID 19802583 DOI: 10.1007/978-3-642-02215-9-10 |
0.398 |
|
| 2009 |
Durbin AP, Setse R, Omer SB, Palmer JG, Spaeder JA, Baker J, Lessans F, Halsey NA. Monitoring adverse events following yellow fever vaccination using an integrated telephone and Internet-based system. Vaccine. 27: 6143-7. PMID 19712766 DOI: 10.1016/J.Vaccine.2009.08.024 |
0.332 |
|
| 2009 |
Ellis RD, Mullen GE, Pierce M, Martin LB, Miura K, Fay MP, Long CA, Shaffer D, Saul A, Miller LH, Durbin AP. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine. 27: 4104-9. PMID 19410624 DOI: 10.1016/j.vaccine.2009.04.077 |
0.345 |
|
| 2009 |
Crompton PD, Mircetic M, Weiss G, Baughman A, Huang CY, Topham DJ, Treanor JJ, Sanz I, Lee FE, Durbin AP, Miura K, Narum DL, Ellis RD, Malkin E, Mullen GE, et al. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. Journal of Immunology (Baltimore, Md. : 1950). 182: 3318-26. PMID 19234231 DOI: 10.4049/Jimmunol.0803596 |
0.328 |
|
| 2008 |
McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, Schmidt AC, Blaney JE, Murphy BR, Whitehead SS. Phase I clinical evaluation of rDEN4Δ30-200,201: A live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity American Journal of Tropical Medicine and Hygiene. 79: 678-684. PMID 18981503 |
0.405 |
|
| 2008 |
Vasilakis N, Durbin AP, da Rosa AP, Munoz-Jordan JL, Tesh RB, Weaver SC. Antigenic relationships between sylvatic and endemic dengue viruses. The American Journal of Tropical Medicine and Hygiene. 79: 128-32. PMID 18606776 |
0.37 |
|
| 2008 |
Wright PF, Ankrah S, Henderson SE, Durbin AP, Speicher J, Whitehead SS, Murphy BR, Pletnev AG. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. Vaccine. 26: 882-90. PMID 18207289 DOI: 10.1016/j.vaccine.2007.12.015 |
0.423 |
|
| 2007 |
Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nature Reviews. Microbiology. 5: 518-28. PMID 17558424 DOI: 10.1038/nrmicro1690 |
0.388 |
|
| 2006 |
Durbin AP, McArthur JH, Marron JA, Blaney JE, Thumar B, Wanionek K, Murphy BR, Whitehead SS. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. Human Vaccines. 2: 255-60. PMID 17106267 |
0.385 |
|
| 2006 |
Durbin AP, McArthur J, Marron JA, Blaney JE, Thumar B, Wanionek K, Murphy BR, Whitehead SS. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Human Vaccines. 2: 167-73. PMID 17012875 |
0.384 |
|
| 2006 |
Blaney JE, Durbin AP, Murphy BR, Whitehead SS. Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunology. 19: 10-32. PMID 16553547 DOI: 10.1089/vim.2006.19.10 |
0.398 |
|
| 2005 |
Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, Mullen GE, Orcutt A, Muratova O, Awkal M, Zhou H, Wang J, Stowers A, Long CA, Mahanty S, ... ... Durbin AP, et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infection and Immunity. 73: 3677-85. PMID 15908397 DOI: 10.1128/IAI.73.6.3677-3685.2005 |
0.377 |
|
| 2005 |
Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine. 23: 3131-8. PMID 15837212 DOI: 10.1016/j.vaccine.2004.12.019 |
0.386 |
|
| 2005 |
Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE, Thumar B, Murphy BR, Karron RA. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. The Journal of Infectious Diseases. 191: 710-8. PMID 15688284 DOI: 10.1086/427780 |
0.36 |
|
| 2000 |
Durbin AP, Elkins WR, Murphy BR. African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection Vaccine. 18: 2462-2469. PMID 10738104 |
0.385 |
|
| Show low-probability matches. |